Todd E Golde

List of Publications by Year in Descending Order

258 papers	23,636 citations	79 h-index	148 g-index
281 ext. papers	26,930 ext. citations	10.1 avg, IF	6.8 L-index

#	Paper	IF	Citations
258	AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model.. *EMBO Molecular Medicine*, **2022**, e09824	12	2
257	Alzheimer's disease - the journey of a healthy brain into organ failure.. *Molecular Neurodegeneration*, **2022**, 17, 18	19	3
256	Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90.. *Scientific Reports*, **2022**, 12, 6117	4.9	1
255	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.. *Neurotherapeutics*, **2022**, 1	6.4	2
254	Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice.. *Communications Biology*, **2022**, 5, 446	6.7	
253	Alzheimer's disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regions. *Journal of Clinical Investigation*, **2021**,	15.9	1
252	Precision therapeutic targets for COVID-19. *Virology Journal*, **2021**, 18, 66	6.1	15
251	Soluble □synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	22
250	Modulating innate immune activation states impacts the efficacy of specific A□immunotherapy. *Molecular Neurodegeneration*, **2021**, 16, 32	19	1
249	Microglia show differential transcriptomic response to A□peptide aggregates ex vivo and in vivo. *Life Science Alliance*, **2021**, 4,	5.8	2
248	Utility of Plasma Neurofilament Light in the 1Florida Alzheimer's Disease Research Center (ADRC). *Journal of Alzheimer's Disease*, **2021**, 79, 59-70	4.3	4
247	Targeting Notch in oncology: the path forward. *Nature Reviews Drug Discovery*, **2021**, 20, 125-144	64.1	53
246	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. *JAMA Neurology*, **2021**, 78, 102-113	17.2	32
245	Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes. *Molecular Therapy*, **2021**, 29, 859-872	11.7	9
244	Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease. *Alzheimer's and Dementia*, **2021**, 17, 984-1004	1.2	9
243	Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions. *Acta Neuropathologica*, **2021**, 141, 359-381	14.3	5
242	□Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse □secretase modulators do not. *Alzheimer's Research and Therapy*, **2020**, 12, 61	9	1

241	CD28 Signaling Drives Notch Ligand Expression on CD4 T Cells. *Frontiers in Immunology*, **2020**, 11, 735	8.4	5
240	Do infections have a role in the pathogenesis of Alzheimer disease?. *Nature Reviews Neurology*, **2020**, 16, 193-197	15	43
239	Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS. *Molecular Neurodegeneration*, **2020**, 15, 15	19	2
238	Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. *Nature Medicine*, **2020**, 26, 769-780	50.5	226
237	Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-*Brain Structure and Function*, **2020**, 225, 427-439	4	8
236	Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy. *Molecular Neurobiology*, **2020**, 57, 1986-2001	6.2	4
235	Atlas of Transcription Factor Binding Sites from ENCODE DNase Hypersensitivity Data across 27 Tissue Types. *Cell Reports*, **2020**, 32, 108029	10.6	9
234	Metformin inhibits RAN translation through PKR pathway and mitigates disease in ALS/FTD mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 18591-18599	11.5	30
233	Fyn depletion ameliorates tau-induced neuropathology. *Acta Neuropathologica Communications*, **2020**, 8, 108	7.3	6
232	Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. *Cell Reports*, **2020**, 32, 107908	10.6	68
231	A40 displays amyloidogenic properties in the non-transgenic mouse brain but does not exacerbate A42 toxicity in Drosophila. *Alzheimer's Research and Therapy*, **2020**, 12, 132	9	1
230	Diversity in A deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis. *Acta Neuropathologica Communications*, **2020**, 8, 43	7.3	6
229	Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 24, 101985	5.3	13
228	Cardiac MLC2 kinase is localized to the Z-disc and interacts with actinin2. *Scientific Reports*, **2019**, 9, 12580	4.9	3
227	Individual and combined presenilin 1 and 2 knockouts reveal that both have highly overlapping functions in HEK293T cells. *Journal of Biological Chemistry*, **2019**, 294, 11276-11285	5.4	8
226	APP-Mediated Signaling Prevents Memory Decline in Alzheimer's Disease Mouse Model. *Cell Reports*, **2019**, 27, 1345-1355.e6	10.6	9
225	Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. *Neuron*, **2019**, 101, 1003-1015	13.9	18
224	Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. *Alzheimer's Research and Therapy*, **2019**, 11, 16	9	54

223	MAPT mutations, tauopathy, and mechanisms of neurodegeneration. *Laboratory Investigation*, **2019**, 99, 912-928	5.9	84
222	A cognitive stress test for prodromal Alzheimer's disease: Multiethnic generalizability. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 550-559	5.2	9
221	Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. *Human Molecular Genetics*, **2019**, 28, 3255-3269	5.6	8
220	Neurite orientation dispersion and density imaging reveals white matter and hippocampal microstructure changes produced by Interleukin-6 in the TgCRND8 mouse model of amyloidosis. *NeuroImage*, **2019**, 202, 116138	7.9	19
219	Intra- and extracellular β-amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus. *Scientific Reports*, **2019**, 9, 15936	4.9	8
218	rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies. *Journal of Experimental Medicine*, **2019**, 216, 539-555	16.6	22
217	An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes. *Journal of Experimental Medicine*, **2019**, 216, 2479-2491	16.6	3
216	Organotypic brain slice cultures to model neurodegenerative proteinopathies. *Molecular Neurodegeneration*, **2019**, 14, 45	19	25
215	Phosphorylation of serine 305 in tau inhibits aggregation. *Neuroscience Letters*, **2019**, 692, 187-192	3.3	15
214	ALS-Linked SOD1 Mutants Enhance Neurite Outgrowth and Branching in Adult Motor Neurons. *IScience*, **2019**, 11, 294-304	6.1	12
213	Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. *Molecular Psychiatry*, **2019**, 24, 1383-1397	15.1	26
212	Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. *Journal of Biological Chemistry*, **2018**, 293, 2408-2421	5.4	54
211	Increased brain hemopexin levels improve outcomes after intracerebral hemorrhage. *Journal of Cerebral Blood Flow and Metabolism*, **2018**, 38, 1032-1046	7.3	25
210	Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. *Frontiers in Immunology*, **2018**, 9, 1288	8.4	31
209	Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy. *Acta Neuropathologica*, **2018**, 136, 709-727	14.3	28
208	Ifngr1 and Stat1 mediated canonical Ifn-γ signaling drives nigrostriatal degeneration. *Neurobiology of Disease*, **2018**, 110, 133-141	7.5	4
207	Short Aβ peptides attenuate Aβ42 toxicity in vivo. *Journal of Experimental Medicine*, **2018**, 215, 283-301	16.6	33
206	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. *Alzheimer's and Dementia*, **2018**, 14, 352-366	1.2	72

205	Notch Signaling Regulates Mitochondrial Metabolism and NF-B Activity in Triple-Negative Breast Cancer Cells via IKKDependent Non-canonical Pathways. *Frontiers in Oncology*, **2018**, 8, 575	5.3	46
204	DDIS-06. AAV TOOLKIT ENABLING PRECISION COMBINATORIAL VIROTHERAPY FOR GLIOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi70-vi70	1	78
203	Alzheimer's disease: The right drug, the right time. *Science*, **2018**, 362, 1250-1251	33.3	80
202	Designing antibodies against LRRK2-targeted tau epitopes. *PLoS ONE*, **2018**, 13, e0204367	3.7	
201	Animal models of neurodegenerative diseases. *Nature Neuroscience*, **2018**, 21, 1370-1379	25.5	204
200	High-affinity interactions and signal transduction between Aligomers and TREM2. *EMBO Molecular Medicine*, **2018**, 10,	12	49
199	Motor neuron loss and neuroinflammation in a model of synuclein-induced neurodegeneration. *Neurobiology of Disease*, **2018**, 120, 98-106	7.5	20
198	TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. *Journal of Experimental Medicine*, **2018**, 215, 2247-2264	16.6	21
197	Notch1 primes CD4 T cells for T helper type I differentiation through its early effects on miR-29. *Molecular Immunology*, **2018**, 99, 191-198	4.3	13
196	Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. *PLoS ONE*, **2018**, 13, e0195211	3.7	10
195	Amyloid peptides overexpression in retinal pigment epithelial cells via AAV-mediated gene transfer mimics AMD-like pathology in mice. *Scientific Reports*, **2017**, 7, 3222	4.9	18
194	Parkinson Disease and Autoimmune Disorders-What Can We Learn From Genome-wide Pleiotropy?. *JAMA Neurology*, **2017**, 74, 769-770	17.2	2
193	Inflammatory pre-conditioning restricts the seeded induction of synuclein pathology in wild type mice. *Molecular Neurodegeneration*, **2017**, 12, 1	19	49
192	A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. *Alzheimer's and Dementia*, **2017**, 13, 663-673	1.2	35
191	A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking. *PLoS ONE*, **2017**, 12, e0173565	3.7	18
190	Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience. *Genome Medicine*, **2017**, 9, 100	14.4	40
189	Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. *Acta Neuropathologica Communications*, **2017**, 5, 58	7.3	26
188	Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. *EMBO Molecular Medicine*, **2017**, 9, 950-966	12	77

187	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature Genetics*, **2017**, 49, 1373-1384	36.3	508
186	Recovery from Proactive Semantic Interference and MRI Volume: A Replication and Extension Study. *Journal of Alzheimer's Disease*, **2017**, 59, 131-139	4.3	22
185	Intrastriatal injection of synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. *Molecular Neurodegeneration*, **2017**, 12, 40	19	35
184	Targeting psychologic stress signaling pathways in Alzheimer's disease. *Molecular Neurodegeneration*, **2017**, 12, 49	19	30
183	Proteolysis of synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. *Journal of Neurochemistry*, **2017**, 140, 662-678	6	41
182	A novel panel of synuclein antibodies reveal distinctive staining profiles in synucleinopathies. *PLoS ONE*, **2017**, 12, e0184731	3.7	32
181	Holdase activity of secreted Hsp70 masks amyloid-42 neurotoxicity in Drosophila. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E5212-21	11.5	46
180	Alzheimer disease: Host immune defence, amyloid- peptide and Alzheimer disease. *Nature Reviews Neurology*, **2016**, 12, 433-4	15	18
179	Deficiency in either COX-1 or COX-2 genes does not affect amyloid beta protein burden in amyloid precursor protein transgenic mice. *Biochemical and Biophysical Research Communications*, **2016**, 478, 286-292	3.4	5
178	Microglia-specific targeting by novel capsid-modified AAV6 vectors. *Molecular Therapy - Methods and Clinical Development*, **2016**, 3, 16026	6.4	55
177	Non-prion-type transmission in A53T synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust synuclein pathology. *Acta Neuropathologica*, **2016**, 131, 151-4	14.3	17
176	Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. *Journal of Neurochemistry*, **2016**, 139 Suppl 2, 224-236	6	15
175	Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. *Acta Neuropathologica*, **2016**, 132, 197-211	14.3	35
174	The stress response neuropeptide CRF increases amyloid- production by regulating secretase activity. *EMBO Journal*, **2015**, 34, 1674-86	13	40
173	Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice. *Molecular Therapy*, **2015**, 23, 53-62	11.7	35
172	A human monoclonal IgG that binds assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo. *Journal of Neuroscience*, **2015**, 35, 6265-76	6.6	18
171	Anti-A single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease. *Human Molecular Genetics*, **2015**, 24, 6093-105	5.6	16
170	IFN- promotes phosphorylation without affecting mature tangles. *FASEB Journal*, **2015**, 29, 4384-98	0.9	19

169	Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice. *Molecular Neurodegeneration*, **2015**, 10, 25	19	40
168	Studies of lipopolysaccharide effects on the induction of -synuclein pathology by exogenous fibrils in transgenic mice. *Molecular Neurodegeneration*, **2015**, 10, 32	19	27
167	Modulation of A42 in vivo by -secretase modulator in primates and humans. *Alzheimer's Research and Therapy*, **2015**, 7, 55	9	8
166	p53 Modulates Notch Signaling in MCF-7 Breast Cancer Cells by Associating With the Notch Transcriptional Complex Via MAML1. *Journal of Cellular Physiology*, **2015**, 230, 3115-27	7	21
165	-Secretase Modulators and APH1 Isoforms Modulate -Secretase Cleavage but Not Position of -Cleavage of the Amyloid Precursor Protein (APP). *PLoS ONE*, **2015**, 10, e0144758	3.7	10
164	Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission. *Acta Neuropathologica*, **2015**, 130, 303-5	14.3	7
163	Re-Opening the Critical Window for Estrogen Therapy. *Journal of Neuroscience*, **2015**, 35, 16077-93	6.6	38
162	Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. *Neurobiology of Aging*, **2015**, 36, 1097-104	5.6	86
161	IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. *Neuron*, **2015**, 85, 519-33	13.9	242
160	Differential Inhibition of Signal Peptide Peptidase Family Members by Established -Secretase Inhibitors. *PLoS ONE*, **2015**, 10, e0128619	3.7	10
159	Amyloidogenic -synuclein seeds do not invariably induce rapid, widespread pathology in mice. *Acta Neuropathologica*, **2014**, 127, 645-65	14.3	91
158	Brain injection of -synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. *Journal of Neuroscience*, **2014**, 34, 12368-78	6.6	99
157	Open questions for Alzheimer's disease immunotherapy. *Alzheimer's Research and Therapy*, **2014**, 6, 3	9	59
156	Intramuscular injection of -synuclein induces CNS -synuclein pathology and a rapid-onset motor phenotype in transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10732-7	11.5	229
155	The effect of brief neonatal cryoanesthesia on physical development and adult cognitive function in mice. *Behavioural Brain Research*, **2014**, 259, 253-60	3.4	9
154	O2-06-03: CAN WE TARGET CORTICOTROPIN RELEASING FACTOR (CRF) FOR THERAPEUTIC BENEFIT IN AD? **2014**, 10, P175-P175		
153	Independent relationship between amyloid precursor protein (APP) dimerization and -secretase processivity. *PLoS ONE*, **2014**, 9, e111553	3.7	22
152	Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. *Journal of Neuroscience*, **2014**, 34, 3826-40	6.6	116

151	-secretase processing and effects of -secretase inhibitors and modulators on long A peptides in cells. *Journal of Biological Chemistry*, **2014**, 289, 3276-87	5.4	21
150	NOTCH1 Can Initiate NF-B Activation via Cytosolic Interactions with Components of the T Cell Signalosome. *Frontiers in Immunology*, **2014**, 5, 249	8.4	38
149	Non-Canonical Notch Signaling Drives Activation and Differentiation of Peripheral CD4(+) T Cells. *Frontiers in Immunology*, **2014**, 5, 54	8.4	52
148	Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of -synuclein. *Journal of Neurochemistry*, **2014**, 131, 859-67	6	87
147	Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. *Journal of Visualized Experiments*, **2014**, 51863	1.6	64
146	Differences in memory development among C57BL/6NCrl, 129S2/SvPasCrl, and FVB/NCrl mice after delay and trace fear conditioning. *Comparative Medicine*, **2014**, 64, 4-12	1.6	9
145	Normal cognition in transgenic BRI2-A mice. *Molecular Neurodegeneration*, **2013**, 8, 15	19	57
144	Conformational templating of -synuclein aggregates in neuronal-glial cultures. *Molecular Neurodegeneration*, **2013**, 8, 17	19	52
143	Induction of CNS -synuclein pathology by fibrillar and non-amyloidogenic recombinant -synuclein. *Acta Neuropathologica Communications*, **2013**, 1, 38	7.3	67
142	Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. *Acta Neuropathologica*, **2013**, 126, 39-50	14.3	20
141	Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo. *European Journal of Neuroscience*, **2013**, 37, 1203-20	3.5	81
140	Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems. *Alzheimer's Research and Therapy*, **2013**, 5, 10	9	42
139	Anti-tau antibodies: hitting the target. *Neuron*, **2013**, 80, 254-6	13.9	15
138	S1 1 4: Cholesterol metabolites as endogenous gamma-secretase modulators **2013**, 9, P121-P122		
137	Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions. *Brain Research*, **2013**, 1524, 62-73	3.7	29
136	The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence. *Biological Psychiatry*, **2013**, 74, 321-8	7.9	22
135	Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. *Journal of Neuroscience*, **2013**, 33, 3765-79	6.6	39
134	Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?. *Alzheimer's Research and Therapy*, **2013**, 5, 26	9	1

133	Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2013**, 5, 24	9	27
132	β-secretase inhibitors and modulators. *Biochimica Et Biophysica Acta - Biomembranes*, **2013**, 1828, 2898-907	3.8	190
131	Steroids as γ-secretase modulators. *FASEB Journal*, **2013**, 27, 3775-85	0.9	32
130	Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. *Journal of Experimental Medicine*, **2013**, 210, 1311-29	16.6	57
129	Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. *Journal of Clinical Investigation*, **2013**, 123, 4158-69	15.9	169
128	Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. *PLoS ONE*, **2013**, 8, e67680	3.7	103
127	Thinking laterally about neurodegenerative proteinopathies. *Journal of Clinical Investigation*, **2013**, 123, 1847-55	15.9	80
126	5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. *Annals of Neurology*, **2012**, 72, 442-54	9.4	62
125	β-secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. *EMBO Molecular Medicine*, **2012**, 4, 980-91	12	109
124	Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. *Molecular Neurodegeneration*, **2012**, 7, 1	19	62
123	Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy. *Vascular Cell*, **2012**, 4, 7	1	60
122	Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases. *Journal of Medicinal Chemistry*, **2012**, 55, 10749-65	8.3	35
121	Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. *Molecular Neurodegeneration*, **2012**, 7, 53	19	52
120	Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology. *Molecular Neurodegeneration*, **2012**, 7, 39	19	28
119	Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. *Molecular Neurodegeneration*, **2012**, 7, 36	19	78
118	Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. *Alzheimer's Research and Therapy*, **2012**, 4, 21	9	24
117	Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. *Alzheimer's Research and Therapy*, **2012**, 4, 18	9	81
116	Recent Alzheimer's disease research highlights. *Alzheimer's Research and Therapy*, **2012**, 4, 14	9	

115	Shifting a complex debate on β-secretase cleavage and Alzheimer's disease. *EMBO Journal*, **2012**, 31, 2237-9	13	7
114	Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 21486-91	11.5	71
113	Alzheimer's β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid. *Journal of Neuroscience*, **2012**, 32, 11390-5	6.6	88
112	Retention in endoplasmic reticulum 1 (RER1) modulates amyloid-β (Aβ) production by altering trafficking of γ-secretase and amyloid precursor protein (APP). *Journal of Biological Chemistry*, **2012**, 287, 40629-40	5.4	24
111	Analysis of proteolytic processes and enzymatic activities in the generation of huntingtin n-terminal fragments in an HEK293 cell model. *PLoS ONE*, **2012**, 7, e50750	3.7	10
110	Right sizing funding for Alzheimer's disease. *Alzheimer's Research and Therapy*, **2011**, 3, 17	9	2
109	Anti-Aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. *Neuron*, **2011**, 69, 203-13	13.9	303
108	Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo. *Molecular Neurodegeneration*, **2011**, 6, 16	19	90
107	Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. *Journal of Biological Chemistry*, **2011**, 286, 39794-803	5.4	29
106	Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. *Journal of Neuroscience*, **2011**, 31, 4124-36	6.6	81
105	Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid β peptide length: support for a sequential model of γ-secretase intramembrane proteolysis and regulation by the amyloid β precursor protein (APP) juxtamembrane region. *Journal of Biological Chemistry*, **2011**, 286, 39804-12	5.4	46
104	Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification. *Nature Neuroscience*, **2011**, 14, 694-6	25.5	54
103	Anesthetic propofol attenuates the isoflurane-induced caspase-3 activation and Aβ oligomerization. *PLoS ONE*, **2011**, 6, e27019	3.7	52
102	Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome. *PLoS ONE*, **2011**, 6, e27221	3.7	69
101	IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. *Journal of Immunology*, **2010**, 184, 5333-43	5.3	139
100	Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. *Journal of Neuroscience*, **2010**, 30, 15374-82	6.6	85
99	Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. *FASEB Journal*, **2010**, 24, 548-59	0.9	236
98	Reduced Alzheimer's disease β-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin. *Journal of Neuroscience*, **2010**, 30, 16160-9	6.6	34

97	Sorting out frontotemporal dementia?. *Neuron*, **2010**, 68, 601-3	13.9	6
96	Targeting Abeta and tau in Alzheimer's disease, an early interim report. *Experimental Neurology*, **2010**, 223, 252-66	5.7	68
95	The secretases: enzymes with therapeutic potential in Alzheimer disease. *Nature Reviews Neurology* , **2010**, 6, 99-107	15	585
94	Targeting Notch to target cancer stem cells. *Clinical Cancer Research*, **2010**, 16, 3141-52	12.9	371
93	Current and Future Therapies for Alzheimer Disease **2010**, 711-774		
92	Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. *Journal of Neuroscience Methods*, **2010**, 194, 144-53	3	51
91	Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. *Anticancer Research*, **2010**, 30, 3853-67	2.3	104
90	A small molecule inhibitor of signal peptide peptidase inhibits Plasmodium development in the liver and decreases malaria severity. *PLoS ONE*, **2009**, 4, e5078	3.7	23
89	Notch regulates cytolytic effector function in CD8+ T cells. *Journal of Immunology*, **2009**, 182, 3380-9	5.3	106
88	Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. *Cancer Research*, **2009**, 69, 2607-14	10.1	65
87	Medicine. Avoiding unintended toxicity. *Science*, **2009**, 324, 603-4	33.3	7
86	Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. *Neurobiology of Disease*, **2009**, 34, 163-77	7.5	204
85	The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. *Molecular Neurodegeneration*, **2009**, 4, 8	19	42
84	Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia. *Nature Neuroscience*, **2009**, 12, 1300-7	25.5	211
83	Signal peptide peptidases: a family of intramembrane-cleaving proteases that cleave type 2 transmembrane proteins. *Seminars in Cell and Developmental Biology*, **2009**, 20, 225-30	7.5	55
82	Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. *Alzheimer's Research and Therapy*, **2009**, 1, 5	9	65
81	Welcome to Alzheimer's research & therapy. *Alzheimer's Research and Therapy*, **2009**, 1, 1	9	5
80	Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 7607-12	11.5	433

79	Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimerβ disease. *Molecular Therapy*, **2009**, 17, 2031-40	11.7	40
78	Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. *Blood*, **2009**, 113, 1689-98	2.2	145
77	Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. *Laboratory Investigation*, **2008**, 88, 11-7	5.9	179
76	Substrate-targeting gamma-secretase modulators. *Nature*, **2008**, 453, 925-9	50.4	261
75	BRI2 (ITM2b) inhibits Abeta deposition in vivo. *Journal of Neuroscience*, **2008**, 28, 6030-6	6.6	93
74	Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. *Journal of Biological Chemistry*, **2008**, 283, 17049-54	5.4	64
73	Transthyretin protects Alzheimerβ mice from the behavioral and biochemical effects of Abeta toxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 2681-6	11.5	222
72	A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 10595-600	11.5	37
71	Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. *Current Topics in Medicinal Chemistry*, **2008**, 8, 47-53	3	39
70	Using leucine zipper to facilitate alpha-synuclein assembly. *FASEB Journal*, **2008**, 22, 3165-74	0.9	10
69	Notch signaling is activated by TLR stimulation and regulates macrophage functions. *European Journal of Immunology*, **2008**, 38, 174-83	6.1	172
68	A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 6392-5	2.9	54
67	Novel rat Alzheimerβ disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. *Molecular Neurodegeneration*, **2007**, 2, 11	19	56
66	Abeta40 inhibits amyloid deposition in vivo. *Journal of Neuroscience*, **2007**, 27, 627-33	6.6	280
65	Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase. *Journal of Biological Chemistry*, **2007**, 282, 32264-73	5.4	66
64	Notch inhibition in Kaposiβ sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-kappaB signaling. *Molecular Cancer Therapeutics*, **2007**, 6, 1983-92	6.1	33
63	Statins reduce amyloid-beta production through inhibition of protein isoprenylation. *Journal of Biological Chemistry*, **2007**, 282, 26832-26844	5.4	130
62	Beta-secretase regulation in aging and disease. *FASEB Journal*, **2007**, 21, A278	0.9	

61	Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. *Brain*, **2006**, 129, 3103-14	11.2	99
60	Filling the gaps in the abeta cascade hypothesis of Alzheimerβ disease. *Current Alzheimer Research*, **2006**, 3, 421-30	3	111
59	Notch signaling in cancer. *Current Molecular Medicine*, **2006**, 6, 905-18	2.5	201
58	Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. *Journal of Neuroscience*, **2006**, 26, 11923-8	6.6	112
57	Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimerβ disease mouse models. *FASEB Journal*, **2006**, 20, 2576-8	0.9	97
56	Intramembrane proteolytic cleavage by human signal peptide peptidase like 3 and malaria signal peptide peptidase. *FASEB Journal*, **2006**, 20, 1671-9	0.9	40
55	Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. *Molecular Therapy*, **2006**, 13, 517-27	11.7	156
54	Detection of presenilin-1 homodimer formation in intact cells using fluorescent lifetime imaging microscopy. *Biochemical and Biophysical Research Communications*, **2006**, 340, 668-74	3.4	24
53	Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice. *Journal of Hepatology*, **2006**, 44, 1105-14	13.4	80
52	Dysfunction of TGF-beta signaling in Alzheimerβ disease. *Journal of Clinical Investigation*, **2006**, 116, 2855-7	15.9	37
51	C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation. *Journal of Neurochemistry*, **2006**, 96, 218-27	6	79
50	Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42. *Journal of Neurochemistry*, **2006**, 96, 355-65	6	31
49	Disease modifying therapy for AD?. *Journal of Neurochemistry*, **2006**, 99, 689-707	6	105
48	Notch1 augments NF-kappaB activity by facilitating its nuclear retention. *EMBO Journal*, **2006**, 25, 129-38	23	248
47	Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. *Journal of Clinical Investigation*, **2006**, 116, 193-201	15.9	155
46	Homing in on intracellular Abeta?. *Neuron*, **2005**, 45, 639-42	13.9	23
45	Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. *Neuron*, **2005**, 47, 191-199	13.9	463
44	The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. *Brain Pathology*, **2005**, 15, 84-7	6	82

43	Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. *Nature Medicine*, **2005**, 11, 545-50	50.5	254
42	Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. *Oncogene*, **2005**, 24, 6333-44	9.2	178
41	Inhibitors of γ-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. *Nature Immunology*, **2005**, 6, 680-688	19.1	232
40	Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. *Nature Immunology*, **2005**, 6, 680-8	19.1	133
39	A signal peptide peptidase (SPP) reporter activity assay based on the cleavage of type II membrane protein substrates provides further evidence for an inverted orientation of the SPP active site relative to presenilin. *Journal of Biological Chemistry*, **2004**, 279, 43148-56	5.4	47
38	Signal peptide peptidase forms a homodimer that is labeled by an active site-directed gamma-secretase inhibitor. *Journal of Biological Chemistry*, **2004**, 279, 15153-60	5.4	72
37	Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity. *Biochemical and Biophysical Research Communications*, **2004**, 322, 1145-52	3.4	27
36	Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. *Journal of Biological Chemistry*, **2003**, 278, 30748-54	5.4	105
35	The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. *Journal of Biological Chemistry*, **2003**, 278, 31825-30	5.4	63
34	Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis. *Science Signaling*, **2003**, 2003, RE4	8.8	27
33	Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. *Journal of Neuroscience*, **2003**, 23, 8532-8	6.6	191
32	Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. *Journal of Biological Chemistry*, **2003**, 278, 31831-7	5.4	226
31	NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. *Journal of Clinical Investigation*, **2003**, 112, 440-9	15.9	382
30	Peptide-based, irreversible inhibitors of gamma-secretase activity. *Biochemical and Biophysical Research Communications*, **2003**, 305, 529-33	3.4	2
29	Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies. *Neurobiology of Aging*, **2003**, 24, 969-76	5.6	29
28	Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron*, **2003**, 39, 409-21	13.9	3031
27	TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. *Journal of Immunology*, **2003**, 171, 3019-24	5.3	200
26	Overexpression of nicastrin increases Abeta production. *FASEB Journal*, **2003**, 17, 1138-40	0.9	31

25	Alzheimer disease therapy: Can the amyloid cascade be halted?. *Journal of Clinical Investigation*, **2003**, 111, 11-18	15.9	116
24	Alzheimer disease therapy: can the amyloid cascade be halted?. *Journal of Clinical Investigation*, **2003**, 111, 11-8	15.9	42
23	Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease. *Drug Development Research*, **2002**, 56, 415-420	5.1	2
22	A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 4697-702	11.5	246
21	Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 6334-9	11.5	91
20	Identification of a novel family of presenilin homologues. *Human Molecular Genetics*, **2002**, 11, 1037-44	5.6	139
19	Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. *Neurobiology of Disease*, **2002**, 9, 11-23	7.5	365
18	A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. *Neurobiology of Disease*, **2002**, 9, 269-73	7.5	85
17	A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. *Nature* , **2001**, 414, 212-6	50.4	1228
16	Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. *Drug Discovery Today*, **2001**, 6, 1049-1055	8.8	56
15	Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. *Journal of Biological Chemistry*, **2001**, 276, 38563-9	5.4	30
14	A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor. *Journal of Biological Chemistry*, **2001**, 276, 481-7	5.4	124
13	gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. *Science*, **2001**, 294, 2179-81	33.3	760
12	Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. *Neurobiology of Aging*, **2001**, 22, 721-7	5.6	140
11	beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations. *Molecular Brain Research*, **2001**, 97, 103-13		56
10	Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage. *Journal of Biological Chemistry*, **2000**, 275, 26277-84	5.4	90
9	Cell-free assays for gamma-secretase activity. *FASEB Journal*, **2000**, 14, 2383-6	0.9	103
8	The presenilin 1 C92S mutation increases abeta 42 production. *Biochemical and Biophysical Research Communications*, **2000**, 277, 261-3	3.4	16

7	Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer□s disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2000**, 1502, 172-87	6.9	221
6	Characterization by radiosequencing of the carboxyl-terminal derivatives produced from normal and mutant amyloid □protein precursors. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1994**, 1, 30-38	2.7	18
5	Production of amyloid beta protein from normal amyloid beta-protein precursor (beta APP) and the mutated beta APPS linked to familial Alzheimer□s disease. *Annals of the New York Academy of Sciences*, **1993**, 695, 103-8	6.5	28
4	Normal processing of the Alzheimer□s disease amyloid beta protein precursor generates potentially amyloidogenic carboxyl-terminal derivatives. *Annals of the New York Academy of Sciences*, **1992**, 674, 138-48	6.5	25
3	Secretory processing of the Alzheimer amyloid beta/A4 protein precursor is increased by protein phosphorylation. *Biochemical and Biophysical Research Communications*, **1992**, 187, 1285-90	3.4	107
2	Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer□s disease using PCR. *Neuron*, **1990**, 4, 253-67	13.9	416
1	High affinity interactions and signal transduction between A□oligomers and TREM2		2